These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9824787)

  • 1. Lack of pharmacokinetic interaction between tiagabine and erythromycin.
    Thomsen MS; Groes L; Agersø H; Kruse T
    J Clin Pharmacol; 1998 Nov; 38(11):1051-6. PubMed ID: 9824787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin.
    Snel S; Jansen JA; Pedersen PC; Jonkman JH; van Heiningen PN
    Eur J Clin Pharmacol; 1998 Jun; 54(4):355-7. PubMed ID: 9696964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.
    Gustavson LE; Sommerville KW; Boellner SW; Witt GF; Guenther HJ; Granneman GR
    Am J Ther; 1998 Mar; 5(2):73-9. PubMed ID: 10099041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
    Gustavson LE; Cato A; Boellner SW; Cao GX; Qian JX; Guenther HJ; Sommerville KW
    Am J Ther; 1998 Jan; 5(1):9-16. PubMed ID: 10099032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function.
    Lau AH; Gustavson LE; Sperelakis R; Lam NP; El-Shourbagy T; Qian JX; Layden T
    Epilepsia; 1997 Apr; 38(4):445-51. PubMed ID: 9118850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy.
    Snel S; Jansen JA; Mengel HB; Richens A; Larsen S
    J Clin Pharmacol; 1997 Nov; 37(11):1015-20. PubMed ID: 9505994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy.
    Sachdeo RC; Narang-Sachdeo S; Montgomery PA; Shumaker RC; Perhach JL; Lyness WH; Rosenberg A
    J Clin Pharmacol; 1998 Feb; 38(2):184-90. PubMed ID: 9549651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine.
    Pesco-Koplowitz L; Hassell A; Lee P; Zhou H; Hall N; Wiesinger B; Mechlinski W; Grover M; Hunt T; Smith R; Travers S
    J Clin Pharmacol; 1999 Jan; 39(1):76-85. PubMed ID: 9987703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP3A inhibition on the metabolism of cilostazol.
    Suri A; Forbes WP; Bramer SL
    Clin Pharmacokinet; 1999; 37 Suppl 2():61-8. PubMed ID: 10702888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.
    Tran JQ; Di Cicco RA; Sheth SB; Tucci M; Peng L; Jorkasky DK; Hursting MJ; Benincosa LJ
    J Clin Pharmacol; 1999 May; 39(5):513-9. PubMed ID: 10234600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical implications of pharmacology and pharmacokinetics of tiagabine].
    Pita-Calandre E
    Rev Neurol; 1999 Feb 1-15; 28(3):337-9. PubMed ID: 10714305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.
    Purkins L; Wood N; Ghahramani P; Kleinermans D; Layton G; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):30-6. PubMed ID: 14616411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiagabine: efficacy and safety in adjunctive treatment of partial seizures.
    Crawford P; Meinardi H; Brown S; Rentmeester TW; Pedersen B; Pedersen PC; Lassen LC
    Epilepsia; 2001 Apr; 42(4):531-8. PubMed ID: 11440349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.
    Muirhead GJ; Faulkner S; Harness JA; Taubel J
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):37S-43S. PubMed ID: 11879258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiagabine: absence of kinetic or dynamic interactions with ethanol.
    Kastberg H; Jansen JA; Cole G; Wesnes K
    Drug Metabol Drug Interact; 1998; 14(4):259-73. PubMed ID: 10694933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiagabine.
    Schachter SC
    Epilepsia; 1999; 40 Suppl 5():S17-22. PubMed ID: 10530690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations.
    Brannan MD; Reidenberg P; Radwanski E; Shneyer L; Lin CC; Cayen MN; Affrime MB
    Clin Pharmacol Ther; 1995 Sep; 58(3):269-78. PubMed ID: 7554700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of interaction between tiagabine, a new antiepileptic drug, and the benzodiazepine triazolam.
    Richens A; Marshall RW; Dirach J; Jansen JA; Snel S; Pedersen PC
    Drug Metabol Drug Interact; 1998; 14(3):159-77. PubMed ID: 10366992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin.
    Nave R; Drollmann A; Steinijans VW; Zech K; Bethke TD
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):264-70. PubMed ID: 15968883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.